Lilly's gastric cancer drug meets late-stage goal
Oct 15 (Reuters) - Eli Lilly and Co said a late-stage study of its experimental gastric cancer drug met its main goal of improving overall survival.
The study, compared the drug ramucirumab to a placebo and the drug was tested as a second-line treatment in patients with cancers that originate in the stomach.
The study, named REGARD, also improved survival without the cancer worsening.
- Comedian Joan Rivers 'resting comfortably' at hospital |
- IBM launches Watson system for research, hopes for breakthroughs
- In town halls, U.S. lawmakers hear voter anger over illegal migrants |
- Separatists say will allow 'trapped' Ukrainian forces to withdraw |
- Obama says does not yet have broad strategy for Islamic State